vimseltinib
selective CSF1R kinase inhibitor oral, 30 mg BIW, phase III, cancer from structure-based design Molecular Cancer Therapeutics Deciphera Pharmaceuticals
Molecules of the Month - September 2021
Molecules of the Month
- ETX0462
- milvexian
- GSK3685032
- JNJ-64619178
- vimseltinib
- ARD-2585
- AZD5305
- SAR247799
- IM156
- BMS-986158
- JNJ-67569762
- FRM-024
- LYC-55716
- S-600918